KIF18A as a potential biomarker to distinguish different breast cancer subtypes based on receptor status
Yazarlar (1)
Dr. Öğr. Üyesi Çağlar BERKEL
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
| Makale Türü | Özgün Makale |
| Makale Alt Türü | Uluslararası alan indekslerindeki dergilerde yayınlanan tam makale |
| Dergi Adı | Genome Instability and Disease |
| Dergi ISSN | 2524-7662 |
| Dergi Tarandığı Indeksler | CAS |
| Makale Dili | İngilizce |
| Basım Tarihi | 03-2024 |
| DOI Numarası | 10.1007/s42764-024-00126-8 |
| Makale Linki | https://link.springer.com/article/10.1007/s42764-024-00126-8 |
| Özet |
| The inhibition of KIF18A selectively reduces the viability of chromosomally unstable cancers due to increased mitotic vulnerability. KIF18A expression was also reported to be upregulated and associated with tumor aggressiveness in certain cancer types including breast cancer. Here, I first showed that KIF18A mRNA expression is higher in triple-negative breast cancer (TNBC) than in non-TNBC. I also found that ER (estrogen receptor)-negative and PR (progesterone receptor)-negative breast cancer cells have higher KIF18A mRNA expression compared to ER-positive and PR-positive breast cancer cells, respectively. In contrast, HER2-positive breast tumors have higher KIF18A expression compared to HER2-negative breast tumors. In terms of PAM50 breast cancer subtypes, KIF18A transcript levels were found to be the highest in basal-like breast cancer, followed by HER2-enriched, luminal B, normal-like and ... |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 8 |